Eltropag 25 Tablet - Eltrombopag Olamine | Incepta Pharmaceuticals

What is Eltropag 25 Tablet?

Eltropag 25 Tablet is an oral thrombopoietin (TPO) receptor agonist manufactured by Incepta Pharmaceuticals Ltd., containing Eltrombopag Olamine. It is used to increase platelet counts in patients with certain forms of thrombocytopenia.

Generic Name and Composition

Each film-coated tablet contains Eltrombopag Olamine INN equivalent to Eltrombopag 25 mg.

Indications

• Chronic immune (idiopathic) thrombocytopenic purpura (ITP) in patients with insufficient response to corticosteroids, immunoglobulins, or splenectomy
• Thrombocytopenia associated with chronic hepatitis C, to allow initiation and maintenance of interferon-based therapy
• Severe aplastic anemia in patients with insufficient response to immunosuppressive therapy

How It Works - Mechanism of Action

Eltrombopag is a small-molecule TPO-receptor agonist that interacts with the transmembrane domain of the human thrombopoietin receptor on bone marrow progenitor cells. This interaction initiates signaling cascades that induce proliferation and differentiation of megakaryocyte progenitor cells, ultimately increasing platelet production.

Dosage and Administration

• Usual starting dose in adults with chronic ITP: 50 mg once daily (dose individualized based on platelet response, with lower starting doses in certain populations - follow physician's specific prescription)
• Take on an empty stomach, at least 1 hour before or 2 hours after meals
• Avoid taking with calcium-rich foods, antacids, or mineral supplements (calcium, iron, magnesium, aluminum, selenium, zinc) - separate by at least 4 hours
• Dose is titrated based on platelet count response, typically assessed every 2 weeks, as directed by physician
• Do not exceed the maximum dose recommended by your physician

Side Effects

Common: Headache, nausea, diarrhea, upper respiratory tract infection

Uncommon: Elevated liver enzymes (ALT/AST), myalgia, rash

Rare: Hepatotoxicity, thromboembolic events, cataracts (with long-term use), bone marrow fibrosis, increased risk of hepatocellular carcinoma progression in hepatitis C patients

Drug Interactions

Polyvalent Cation-Containing Products (calcium, iron, magnesium, aluminum, selenium, zinc supplements, antacids): Significantly reduce eltrombopag absorption - separate dosing by at least 4 hours

HMG-CoA Reductase Inhibitors (statins, e.g., rosuvastatin): Eltrombopag may increase plasma concentration of certain statins - dose reduction of statin may be needed

OATP1B1 and BCRP Substrates: Eltrombopag inhibits these transporters and may increase exposure to co-administered substrate drugs

Hepatotoxic Drugs: Concomitant use may increase risk of liver toxicity - monitor liver function closely

Contraindications

• Known hypersensitivity to eltrombopag or any excipient
• Severe hepatic impairment (use with extreme caution and close monitoring if used at all)

Pregnancy and Lactation

Data on use of eltrombopag during pregnancy and lactation are limited. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under direct physician supervision. Discuss breastfeeding plans with your physician, as it is not recommended due to limited safety data.

Precautions and Warnings

• Regular monitoring of liver function tests is required before and during treatment
• Periodic complete blood counts with platelet monitoring are necessary throughout therapy
• Risk of thromboembolic events - use with caution in patients with risk factors for blood clots
• Discontinue if platelet counts rise excessively, to avoid thromboembolic complications - follow physician's monitoring schedule
• Use with caution in patients with hepatic impairment - dose adjustment may be required
• Periodic eye examinations may be recommended with long-term use due to reported cataract risk

Overdose

Overdose may result in excessive platelet count elevation, increasing the risk of thromboembolic complications, or may cause liver enzyme abnormalities. Seek immediate medical attention if overdose is suspected. Management is generally supportive with close monitoring of platelet count and liver function, as directed by a physician.

Storage Instructions

• Store below 30°C in a dry place
• Protect from light and moisture
• Keep in original packaging until time of use
• Keep out of reach of children

Frequently Asked Questions

Q1: What is Eltropag 25 Tablet used for?
A1: It is used to increase platelet counts in patients with chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia, under physician supervision.

Q2: How should I take Eltropag Tablet?
A2: Take on an empty stomach, at least 1 hour before or 2 hours after meals, and avoid calcium-rich foods, antacids, or mineral supplements within 4 hours of dosing.

Q3: Why does Eltropag require regular blood tests?
A3: Regular liver function tests and platelet counts are required to monitor treatment response and detect potential side effects such as liver enzyme elevation or excessive platelet rise, which can increase clotting risk.

Q4: How does Eltropag compare to other treatments for thrombocytopenia available from Incepta?
A4: Eltropag (Eltrombopag) works by stimulating platelet production via TPO-receptor activation, offering an oral option for chronic thrombocytopenia management. Other supportive therapies in Incepta's portfolio target different conditions; your hematologist will determine the most appropriate treatment based on your specific diagnosis and platelet response.

Medical Disclaimer

This medicine is available only with a valid prescription from a registered physician (Rx only). The information provided here is for educational purposes and does not replace professional medical advice. DiabetesStore.com.bd is a licensed online pharmacy in Bangladesh. Please consult your doctor before starting, stopping, or changing any medication.